Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Aardvark Therapeutics in a report released on Monday, March 10th. Cantor Fitzgerald analyst J ...

Cantor Fitzgerald initiated coverage of Aardvark Therapeutics (AARD) with an Overweight rating and $50 price target Aardvark is developing ...

RBC Capital analyst Brian Abrahams initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating and $21 price target Aardvark ...

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

Investment analysts at Bank of America began coverage on shares of Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) in a note issued to investors on Monday, MarketBeat reports. The firm set a ...

The miraculous rescue of elderly Rosalia De Giosa was met with an emotional round of applause from onlookers in Via De Amicis ...

On Monday, RBC Capital initiated coverage on Aardvark Therapeutics Inc (NASDAQ:AARD), awarding the stock an Outperform rating and setting a price target of $21.00. The stock, currently trading at ...

In this article, we are going to take a look at where Aardvark Therapeutics, Inc. (NASDAQ:AARD) stands against other stocks with at least $10 million in insider spending recently. Since Donald ...

While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder.

March 7, 2025 (Investorideas.com Newswire) Investorideas.com, a recognized top 100 investment site for stock news announces ...